Mesoblast (MEOBF) EBITDA Margin Growth (1y) (2015 - 2023)
Powered by 
Analysis
Mesoblast (MEOBF) EBITDA Margin Growth (1y) (2015 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 798.00 |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 2.46 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 13,751.00 |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 2,348.00 |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -6,012.00 |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -2.44 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 375,193.00 |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -1,560.00 |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 377.00 |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -922,959.00 |
| Mar 31, 2023 | 3,732.00 |
| Dec 31, 2022 | -55,257.00 |
| Sep 30, 2022 | -69,257.00 |
| Jun 30, 2022 | -75,329.00 |
| Mar 31, 2022 | 30,223.00 |
| Dec 31, 2021 | 30,239.00 |
| Sep 30, 2021 | 142,552.00 |
| Mar 31, 2021 | -136,334.00 |
| Dec 31, 2020 | -6,397.00 |
| Sep 30, 2020 | -209,538.00 |
| Mar 31, 2020 | 220,247.00 |
| Dec 31, 2019 | 47,531.00 |
| Sep 30, 2019 | 13,406.00 |
| Jun 30, 2019 | -2,088.00 |
| Mar 31, 2019 | -6,222.00 |
| Dec 31, 2018 | -152,992.00 |
| Sep 30, 2018 | 66,988.00 |
| Jun 30, 2018 | 415,432.00 |
| Mar 31, 2018 | -76,566.00 |